share_log

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

SEC announcement ·  Apr 22 13:11
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more